
Dapagliflozin 5 mg daily attenuates CV events among diabetes patients with chronic HF
The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, we investigated whether dapagliflozin suppresses urinary albumin excretion, a …